At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluation of Clinical and Safety Outcomes Associated With Conversion From Brand-Name to Generic Tacrolimus Products in High Risk Transplant Recipients
In Brief
A Phase 4 clinical trial evaluating Prograf, Tacrolimus, Sandoz, and 4 other interventions for Complication of Transplant. Completed, enrolled 71 participants across 1 site.
Detailed Summary
The prospective study will compare the relative bioavailability at steady-state pharmacokinetics of 6 tacrolimus formulations in a prospective, 6-way cross-over study including CYP3A5 expressors (n=30) and non-expressor (n=30) transplant patients.
Study Details
Timeline
Interventions
Administration of each formulation will be determined by sequence.
Administration of each formulation will be determined by sequence.
Administration of each formulation will be determined by sequence.
Administration of each formulation will be determined by sequence.
Administration of each formulation will be determined by sequence.
Administration of each formulation will be determined by sequence.